Paliperidone
Paliperidone structure
|
Common Name | Paliperidone | ||
|---|---|---|---|---|
| CAS Number | 144598-75-4 | Molecular Weight | 426.484 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 612.3±65.0 °C at 760 mmHg | |
| Molecular Formula | C23H27FN4O3 | Melting Point | 158-160°C | |
| MSDS | Chinese USA | Flash Point | 324.1±34.3 °C | |
| Symbol |
GHS06 |
Signal Word | Danger | |
|
Simple and sensitive screening and quantitative determination of 88 psychoactive drugs and their metabolites in blood through LC–MS/MS: Application on postmortem samples
J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 970 , 1-7, (2014) • The introduction has been modified. • More references have been added to the text. • Limitations of the method have been discussed more in detail. |
|
|
The use of dried blood spots for quantification of 15 antipsychotics and 7 metabolites with ultra-high performance liquid chromatography - tandem mass spectrometry.
Drug Test. Anal. 7 , 502-11, (2015) Therapeutic drug monitoring of antipsychotics is important in optimizing individual therapy. In psychiatric populations, classical venous blood sampling is experienced as frightening. Interest in alternative techniques, like dried blood spots (DBS), has conse... |
|
|
Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma.
Mol. Med. Report. 12 , 6501-8, (2015) Cyclin-dependent kinase 2 (CDK2) has been reported to be overexpressed in human colorectal cancer; it is responsible for the G1‑to‑S‑phase transition in the cell cycle and its deregulation is a hallmark of cancer. The present study was the first to use idock,... |
|
|
Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trials.
J. Clin. Psychopharmacol. 33(2) , 157-61, (2013) A post hoc analysis of the risperidone (RIS)/paliperidone (Pali) clinical trials database comprising 64 studies was conducted. Risk of sudden death, cardiovascular (CV), and cerebrovascular events during RIS or Pali treatment was estimated. Treatment emergent... |
|
|
Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews.
Sao. Paulo Med. J. 128(3) , 141-66, (2010) According to some cohort studies, the prevalence of refractory schizophrenia (RS) is 20-40%. Our aim was to evaluate the effectiveness and safety of aripiprazole, paliperidone, quetiapine and risperidone for treating RS. |
|
|
The pharmacokinetics of paliperidone versus risperidone.
Psychosomatics 51(1) , 80-8, (2010) Several new atypical antipsychotics have become available for use, but knowledge about their pharmacology may not be widespread.This review aims to increase awareness and knowledge about risperidone (R) and paliperidone (9-hydroxyrisperidone [9-OHR]), their p... |
|
|
Combination treatment of tamoxifen with risperidone in breast cancer.
PLoS ONE 9(6) , e98805, (2014) Tamoxifen has long been used and still is the most commonly used endocrine therapy for treatment of both early and advanced estrogen receptor-positive breast cancer in pre- and post-menopause women. Tamoxifen exerts its cytotoxic effect primarily through cyto... |
|
|
[Paliperidone, risperidone].
Nihon Rinsho. 71(4) , 654-9, (2013) Risperidone, a serotonin-dopamine antagonist, is effective in preventing delusions and hallucinations by D2 receptor antagonism and treating negative symptoms by 5-HT2A receptor antagonism. It is less likely to produce extrapyramidal symptoms than conventiona... |
|
|
The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.
Pharmacogenet. Genomics 23(9) , 487-93, (2013) To investigate the effect of the Taq1A variant in the Dopamine D2 receptor gene (DRD2) and common functional genetic variants in the cytochrome P450 2D6 gene (CYP2D6) on prolactin levels in risperidone-treated boys with autism spectrum disorders and disruptiv... |
|
|
Johnson & Johnson to pay $2.2bn to settle charges of false marketing on three drugs.
BMJ 347 , f6696, (2013)
|